Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A).
Publication
, Journal Article
Nixon, A; Starr, M; Pang, H; Bulusu, A; Honeycutt, W; Amara, A; Bendell, JC; Hurwitz, H
Published in: Journal of Clinical Oncology
May 20, 2010
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
e21009 / e21009
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Nixon, A., Starr, M., Pang, H., Bulusu, A., Honeycutt, W., Amara, A., … Hurwitz, H. (2010). Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A). Journal of Clinical Oncology, 28(15_suppl), e21009–e21009. https://doi.org/10.1200/jco.2010.28.15_suppl.e21009
Nixon, A., M. Starr, H. Pang, A. Bulusu, W. Honeycutt, A. Amara, J. C. Bendell, and H. Hurwitz. “Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): e21009–e21009. https://doi.org/10.1200/jco.2010.28.15_suppl.e21009.
Nixon A, Starr M, Pang H, Bulusu A, Honeycutt W, Amara A, et al. Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A). Journal of Clinical Oncology. 2010 May 20;28(15_suppl):e21009–e21009.
Nixon, A., et al. “Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. e21009–e21009. Crossref, doi:10.1200/jco.2010.28.15_suppl.e21009.
Nixon A, Starr M, Pang H, Bulusu A, Honeycutt W, Amara A, Bendell JC, Hurwitz H. Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):e21009–e21009.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
e21009 / e21009
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences